Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus UTICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus UTICILLIN VK.
AMOXICILLIN PEDIATRIC vs UTICILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic